New oral chemotherapeutic agents for lung cancer

Drugs

Volumn 58, Issue SUPPL. 3, 1999, Pages 57-69

  Bengtson, Elizabeth M ^a   Rigas, James R ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; NAVELBINE; PLATINUM; SATRAPLATIN; TANOMASTAT; TOPOTECAN; UFT; VINBLASTINE; VINCRISTINE; VINDESINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG METABOLISM; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; LUNG CANCER; METASTASIS; NONHUMAN; QUALITY OF LIFE;

VINCA;

EID: 0033504003     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958003-00009     Document Type: Conference Paper

References (137)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27
2. Anonymous. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909
3. Cullen MH, Woodroffe CM, Billingham L.J, et al. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: 2. Results of a randomised trial in patients with extensive disease-Lung Cancer 1997; 18 Suppl. 1: 5
4. Coates A, Dillenbeck CF, McNeil DR, et al. On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633-7
5. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8
6. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine® on tubulin and associated proteins. Semin Oncol 1989; 16 Suppl. 4:9-14
7. Potier P. The synthesis of Navelbine® - prototype of a new series of vinblastine derivatives. Semin Oncol 1989; 16 Suppl. 4: 2-4
8. Binet S, Fellous A, Lataste H, et al. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989; 16 Suppl. 4: 5-8
9. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-6
10. Krikorian A, Rahmani R, Bromet M, et al. Pharmacokinetics and metabolism of Navelbine®. Semin Oncol 1989; 16 Suppl. 4:21-5
11. Nelson R, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine, and vinblastine in patients with cancer. Cancer Treat Rev 1980; 7 Suppl. 1: 17-24
12. Nelson R. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 1982; 10: 115-27
13. Leveque D, Quoix E, Dumont P, et al. Pulmonary distribution of vinorelbine in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1993; 33: 176-8
14. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesinc and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7
15. Hodes M, Rohn R, Bond W. Vincaleukoblastine III. Clinical trial with the oral preparation. Cancer Chemother Rep 1961, 14: 129-38
16. Korst DR, Nixon JC. Oral administration of vinblastine sulfate (NSC-49842) to cancer patients. Cancer Chemother Rep 1965; 45: 53-6
17. MacDonald Jr CA, Lacher MJ. Oral vinblastine sulfate in Hodgkin's disease. Clin Pharmacol Ther 1966; 7: 534-41
18. Wilson HE, Louis J. The response of Hodgkin's disease to treatment with oral vinblastine sulfate. Ann Intern Med 1967; 67: 303-8
19. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996; 31: 184-97
20. Zhou XJ, Bore P, Monjanel S, et al. Pharmacokinetics of Navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 1991; 29: 66-70
21. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994; 12: 1754-63
22. Bore P, Rahmani R, Van Cantfort J, et al. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Cancer Chemother Pharmacol 1989; 23: 247-51
23. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid Chromatography. Cancer Res 1991; 51: 2073-6
24. Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (navelbine). Semin Oncol 1994; 21 Suppl. 10: 21-7
25. Favre R, Delgado M, Besenval M. Phase I trial of escalating doses of orally administered Navelbine. Pt II. Clinical results. Proc Am Soc Clin Oncol 1989; 8: 64A
26. Rahmani R, Bore P, Cano JP. Phase I trial of escalating doses of orally administered Navelbine. Pt I. Pharmacokinetics. Proc Am Soc Clin Oncol 1989; 8: 74A
27. 3H]Navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anticancer Drugs 1991; 2: 405-10
28. Lucas S, Donehower R, Rowinsky E. Clinical results of a study of the absolute bioavailability and pharmacokinetics of weekly vinorelbine liquid-filled soft gelatin capsules at full therapeutic doses in patients with solid tumors. Proc Am Soc Clin Oncol 1992; 11: 287A
29. Zhou XJ, Zhou-Pan XR, Favre R, et al. Relative bioavailability of two oral formulations of navelbine in cancer patients. Biopharm Drug Dispos 1994; 15: 577-86
30. Vokes EE, Rosenberg RK, Jahanzeb M, et al. Multicenter phase Il study of weekly oral vinorelbine fur stage IV non-small-cell lung cancer. J Clin Oncol 1995; 13: 637-44
31. Depierre A, Lemarie E, Dabouis G, et al. A Phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-9
32. Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-84
33. Spicer D, McCaskill-Stevens W, Oken M, et al. Oral Navelbine in women with previously treated advanced breast cancer: a US multicenler Phase II trial. Proc Am Soc Clin Oncol 1994; 13: 76A
34. Lucas S, Rowinsky E, Wargin W. Results of a study of the effect of food on the bioavailability and pharmacokinetics of Navelbine® liquid-filled soft gelatin capsules. Proc Am Soc Clin Oncol 1993; 12: 160A
35. Rowinsky EK, Lucas VS, Hsieh AL, et al. The effects of food and divided dosing on the hioavailahility of oral vinorelbine. Cancer Chemother Pharmacol 1996; 39: 9-16
36. Winer EP, Chu L, Spicer DV. Oral vinorelbine (navelbine) in the treatment of advanced breast cancer. Semin Oncol 1995; 22 Suppl. 5: 72-8
37. Robieux I, Sorio R, Vitali V, et al. Pharmacokinetics of vinorelbine in breast cancer patients with liver metastases. Proc Am Soc Clin Oncol 1995; 14: 458A
38. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9
39. Rosenberg B, Van Camp L, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 1967; 242: 1347-52
40. Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 385-6
41. Higby DJ, Wallace HJ, Albert DJ, et al. Diammine-dichloroplatinum: a Phase I study showing responses in testicular and other tumors. Cancer 1974; 33: 1219-25
42. Harrap KR, Jones M, Wilkinson CR, et al. Antitumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, editor. Cisplatin: current status and new developments. New York: Academic Press, 1980: 193-212
43. Shea TC, Flaherty M, Elias A, et al. A Phase I clinical and pharmacokinetic study of carhoplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-61
44. Harrap KR, Kelland LR, Jones M, et al. Platinum coordination complexes which circumvent cisplatin resistance. Adv Enzyme Regul 1991; 31: 31-43
45. Harrap KR, Murrer BA, Giandomenico C, et al. A novel class of orally active platinum IV coordination complexes which circumvent cisplatin resistance in vitro. Proc Am Assoc Cancer Res 1991; 32: 428A
46. Harrap KR, Morgan SE, Murrer BA, et al. New platinum drugs capable of oral administration. Ann Oncol 1992; 3 Suppl. 1: 116A
47. Giandomenico CM, Abrams MJ, Murrer BA, et al. Synthesis and reactions of a new class of orally active Pt(IV) antitumor complexes. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Publishing Corp., 1991: 93-100
48. Kelland LR, Murrer BA, Abel G, et al. Structure-activity relationships in a series of novel platinum (II) and platinum (IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J Cell Pharmacol 1991; 2: 331-42
49. Twentyman PR, Wright KA, Mistry P, et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992; 52: 5674-80
50. Kelland LR, Mellish KJ, Abel G, et al. Circumvention of transport-mediated acquired cisplalin resistance in human cancer cell lines by the orally active platinum drug, Bis-acetatoammine dichloro(cyclohexylamine) platinum (IV) (JM216). Proc Am Assoc Cancer Res 1993; 34: 400A
51. Mellish KJ, Kelland LR, Harrap KR In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993; 63: 240-50
52. Rose WC, Crosswell AR, Schurig JE, et al. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chermother Pharmacol 1993; 32: 197-203
53. Harrap KR. Initiatives with platinum- and quinazoline-hased antitumor molecules - Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995; 55: 2761-8
54. Casazza AM, Rose WC, Comereski C, et al. JM 216: a novel orally active platinum complex. Proc Am Assoc Cancer Res 1992; 33: 536A
55. Kelland LR, Mistry P, Abel G, et al. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 1992; 52: 3857-64
56. Kelland LR, Murrer BA, Abel G, et al. Ammine/amine platinum(IV) dicarboxylate complexes: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cells lines. Cancer Res 1992; 52: 822-8
57. McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally administered bis-acetato-ammine-dichlorocyclohexytamine-platinum(IV) (JM216) in vivo. Cancer Res 1994; 54: 4118-22
58. McKeage MJ, Morgan SE, Boxall FE, et al. Preclinical toxicology and tissue platinum distribution of novel oral antitumor platinum complexes: ammine/amine platinum (IV) dicarboxylates. Cancer Chemother Pharmacol 1994; 33: 497-503
59. McKeage MJ, Morgan SE, Boxall FE, et al. Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Br J Cancer 1993; 67: 996-1000
60. Raynaud FI, Boxall FE, Goddard P, et al. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its hiotransformation products. Anticancer Res 1996; 16: 1857-62
61. McKeage MJ, Mistry P, Ward J, et al. A Phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995; 36: 451-8
62. McKeage MJ, Raynaud F, Ward J, et al. Phase 1 and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15: 2691-700
63. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997; 8: 604-6
64. Fokkema E, Lunenberg J, van Putten JWG, et al. Randomized Phase II study of oral JM2 16 versus intravenous cisplatin in non-small cell lung cancer: preliminary results. Proc Am Soc Clin Oncol 1998; 17: 83A
65. Groen HJM, Smit EF, Bauer J, A Phase II study of oral platinum JM-216 as first-line treatment in small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 378A
66. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant eisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-30
67. van de Vaart PJ, Klaren HM, Hofland I, et al. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells. Int J Radiat Biol 1997; 72: 675-83
68. Hoffman P, Mauer A, Haraf D. et al. Oral JM-216 plus concomitant radiotherapy for patients with advanced malignancies of the chest. Proc Am Soc Clin Oncol 1998; 17: 488A
69. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970; 54: 461-70
70. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-21
71. Verweij J. New promising anticancer agents in development: what comes next? Cancer Chemother Pharmacol 1996; 38 Suppl.: S3-S10
72. Creaven PJ, Allen LM, Muggia FM. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 1972; 56: 573-8
73. Moertel CCG, Schult AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rev 1972; 56: 95-101
74. Schmitt B, Buhre U, Vosberg HP. Characterisation of size variant of type I DNA topoisomerase isolated from calf thymus. Eur J Biochem 1984; 144: 127-34
75. Juan C, Hwang J, Liu LF, et al. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q 12-13.2. Proc Natl Acad Sci USA 1988; 85: 8910-3
76. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834-6
77. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-limited DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8
78. Mattern MR, Mong SM, Bartus HF, et al. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 1987; 47: 1793-8
79. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug stabilized topoisomerase-I-DNA cleavahle complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82
80. Liu L. DNA topoisomerasc poisons as antitumor drugs. Ann Rev Biochem 1989; 58: 351-74
81. Creemers GJ, Schellens JHM, Beijnen JH, et al. Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proc Am Soc Clin Oncol 1994; 13: 132A
82. Creemers GJ, Lund B, Verweij J. Topoisomerase 1 inhibitors: lopotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96
83. McCabe FL, Johnson RK. Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan. Cancer Invest 1994; 12: 308-13
84. Creemers GJ, Gerrits CJH, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087-93
85. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8
86. Burris HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20
87. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 1992; 31: 229-39
88. Verweij J, Lund B, Beijnen JH, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993; 4: 673-8
89. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9
90. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6
91. Ardizzoni A, Hansen HH, Dombernowsky P, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer. Eur J Cancer 1995; 31A Suppl. 5: S19
92. Broom C. Clinical studies of topotecan. Ann N Y Acad Sci 1996; 803: 264-71
93. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56
94. Wall JA, Burris HA, Von Hoff DD, et al. A Phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor, topotecan (SK&F 104864), given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337-45
95. Schiller JH, Kim K, Johnson, D. Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 330A
96. Schiller J, Von Pawel J, Shepherd F, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of patients with recurrent small cell lung cancer, a Phase II study. Proc Am Soc Clin Oncol 1998; 17: 456A
97. Schellens JHM, Creemers GJ, Beijnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996; 73: 1268-71
98. Kuhn J, Rizzo J, Eckhardt J, et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995; 14: 474A
99. Kizaki M, Dawson MI, Heyman R, et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemic differentiation and proliferation in vitro. Blood 1996; 87: 1977-84
100. Kizaki M, Nakajima H, Mori S, et al. Novel retinoic acid, 9-cis retinoic acid, in combination with all-Irans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells. Blood 1994; 83: 3289-97
101. Miller VA, Benedetti FM, Rigas JR. et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790-5
102. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994; 37: 2930-41
103. Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146-55
104. Zhang XK, Hoffmann B, Tran PBV, et al. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992; 355: 441-6
105. Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-4
106. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992; 17: 427-33
107. Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15: 3540-51
108. Kligman AM, Fulton JL, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99: 469-76
109. Peck GL, Olsen TG, Yoder KW. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300: 329-33
110. Baden HP, Buxman MM, Weinstein GD, et al. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol 1982; 6 Suppl. 2: 716-20
111. Peck GL, Olsen TG, Butkus D, et al. Isotretinoid versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735-45
112. Lippman SM, Parkinson DR, Itri LM. et al. 13-cis-Retinoic acid and Interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-41
113. Lippman SM, Kavanagh JJ, Paredes Espinoza M, et al. 13-cis-Retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5
114. Benner SE, Winn RJ, Lippman SM, et al. Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemotherapy study. J Natl Cancer Inst 1993; 85: 44-7
115. Benner SE, Lippman SM, Hong WK. Retinoid chemoprevention of second primary tumors. Semin Hematol 1994; 31 Suppl. 5: 26-30
116. Koeffler P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983; 62: 709-21
117. Douer D, Koeffler P. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 1982; 69: 277-83
118. Lotan R, Lotan D, Sacks PG. Inhibition of tumor cell growth by relinoids. Methods Enzymol 1990; 190: 100-10
119. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72
120. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. 1. Clinical results. Blood 1990; 76: 1704-9
121. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic patients. Blood 1991; 78: 1413-9
122. Miller Jr WH, Jakubowski A, Tong WP, et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995; 85: 3021-7
123. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036-41
124. Mehta K, McQueen T, Neamati N. Activation of retinoid receptors RAR-a and RXR-a induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1996; 7: 179-86
125. Shirley MA, Wheelan P, Howell SR, et al. Oxidative metabolism of a retinoid and rapid phase II metabolite identification by mass spectrometry. Drug Metab Dispos 1997; 25: 1144-9
126. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566-70
127. Bischoff ED, Gottardis MM, Moon TE, et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479-84
128. Cawston TE, Galloway WA, Mercer E, et al. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981; 195: 159-65
129. Dean DD, Woessner Jr JF. Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J 1984; 218: 277-80
130. Hasty KA, Reife RA, Kang AH, et al. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990; 33: 388-97
131. Brown PD. Matrix inetalloproteinase inhibitors: a new class of anticancer agent. Curr Opin Invest Drugs 1993; 2: 617-26
132. Hibner B, Card A, Flynn C, et al. Bay 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 1998; 39: 302A
133. Bull C, Flynn C, Eberwein D, et al. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Assoc Cancer Res 1998; 39: 302A
134. Flynn C, Bull C, Eberwein D, et al. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT 116 orthotopic model. Proc Am Assoc Cancer Res 1998; 39: 301A
135. Shah A, Sundaresan P, Humphrey R, et al. Comparative pharmacokinetics of BAY 12-9566, a metalloproteinase inhibitor, in healthy volunteers and cancer patients. Proc Am Assoc Cancer Res 1998; 39: 521A
136. Hirte H, Goel R, Major P, et al. Pharmacokinetics of BAY12-9566: early results of a Canadian Phase I dose escalation study in cancer patients. Proc Am Assoc Cancer Res 1998; 39: 364A
137. Langer CJ. The role of tegafur.uracil in pulmonary malignancy. Drugs 1999; 58 Suppl. 3: 71-5